Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide plus talazoparib in metastatic hormone-naïve prostate cancer
2019-003096-20Phase 2Active
- Sponsor
- MEDSIR
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of talazoparib and enzalutamide in prostate cancer (PCa), sponsored by MEDSIR. Primary endpoint: PSA complete response at 12 months. Started May 2020; status: active.
02
Drugs
talazoparibenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2019-003096-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003096-20.